Taken together, these data suggested that KRAS signaling can suppress miR-34a expression via the PI3K/STAT3 axis, which in turn relieves miR-34a–dependent repression of CD47, leading to escape from innate immune surveillance and tumor progression (Figure 6G). The gene discussed is KRAS; the disease is neoplasm.